Edition:
United Kingdom

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

53.08USD
7 Dec 2018
Change (% chg)

$-0.17 (-0.32%)
Prev Close
$53.25
Open
$53.23
Day's High
$53.79
Day's Low
$52.75
Volume
3,420,658
Avg. Vol
1,943,131
52-wk High
$70.04
52-wk Low
$46.95

Latest Key Developments (Source: Significant Developments)

Bristol-Myers Squibb announces dividend increase
Thursday, 6 Dec 2018 

Dec 6 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB ANNOUNCES DIVIDEND INCREASE.BRISTOL-MYERS SQUIBB CO - DECLARED AN INCREASE OF 2.5% PERCENT IN COMPANY'S QUARTERLY DIVIDEND, BEGINNING IN Q1 OF 2019.BRISTOL-MYERS SQUIBB CO - DIVIDEND INCREASE WILL RESULT IN A QUARTERLY DIVIDEND OF 41 CENTS PER SHARE ON $.10 PAR VALUE COMMON STOCK.  Full Article

Bristol-Myers Squibb to transfer $3.8 bln in U.S. pension liabilities
Monday, 3 Dec 2018 

Dec 3 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB TO TRANSFER $3.8 BILLION IN U.S. PENSION LIABILITIES.BRISTOL-MYERS SQUIBB CO - PLAN HAS SUFFICIENT ASSETS TO SATISFY ALL TRANSACTION OBLIGATIONS; NO COMPANY CASH CONTRIBUTION EXPECTED.BRISTOL-MYERS SQUIBB CO - WILL TRANSFER $3.8 BILLION OF U.S. PENSION OBLIGATIONS THROUGH A FULL TERMINATION OF ITS U.S. RETIREMENT INCOME PLAN.BRISTOL-MYERS -ON PENSION LIABILITY TRANSFER TRANSACTION CLOSE IN Q3, EXPECTS NON-CASH PRE-TAX PENSION SETTLEMENT CHARGE OF ABOUT $1.5 BILLION - $2 BILLION.BRISTOL-MYERS SQUIBB CO - NON-GAAP PENSION RELATED INCOME CONTRIBUTING ABOUT $0.05 EPS IN 2018 IS NOT EXPECTED TO BE RECOGNIZED IN 2019.BRISTOL-MYERS SQUIBB - BENEFITS FROM TRANSFER OF U.S. PENSION LIABILITIES TO BE DISTRIBUTED THROUGH COMBINATION OF LUMP SUM PAYMENTS & PURCHASE OF GROUP ANNUITY CONTRACT FROM ATHENE.  Full Article

Bristol-Myers Squibb Says U.S. FDA Approves New Immunotherapy Combination
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - Bristol-Myers Squibb Co ::U.S. FOOD AND DRUG ADMINISTRATION APPROVES EMPLICITI® (ELOTUZUMAB) PLUS POMALIDOMIDE AND DEXAMETHASONE, A NEW IMMUNOTHERAPY COMBINATION FOR CERTAIN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA.BRISTOL-MYERS SQUIBB CO - LOW DISCONTINUATION RATES DUE TO ADVERSE REACTIONS WERE OBSERVED WITH BOTH EPD AND PD ALONE.BRISTOL-MYERS - EMPLICITI-POMALIDOMIDE-DEXAMETHASONE TREATMENT DOUBLED MEDIAN PROGRESSION-FREE SURVIVAL & OVERALL RESPONSE RATE VERSUS POMALIDOMIDE-DEXAMETHASONE.  Full Article

Bristol-Myers Sees Continued Growth From Opdivo In 2019
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - Bristol-Myers Squibb Co ::SEES CONTINUED GROWTH FROM OPDIVO IN 2019.SAYS ELIQUIS HAS "SIGNIFICANT HEADROOM FOR FURTHER GROWTH".  Full Article

Halozyme Announces First Clinical Dosing In Bristol-Myers Squibb's Phase 1 Trial Of Bms-986179 With Enhanze Technology
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - Halozyme Therapeutics Inc ::HALOZYME ANNOUNCES FIRST CLINICAL DOSING IN BRISTOL-MYERS SQUIBB'S PHASE 1 TRIAL OF BMS-986179 WITH ENHANZE® TECHNOLOGY.HALOZYME - INITIATION OF STUDY TRIGGERED A $5 MILLION MILESTONE PAYMENT TO HALOZYME UNDER COLLABORATION AND LICENSE AGREEMENT BETWEEN COMPANIES.  Full Article

Bristol-Myers Squibb Raises 2018 Adjusted Shr Guidance Range
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB - QTRLY GAAP EPS $1.16; QTRLY NON-GAAP EPS $1.09.BRISTOL-MYERS SQUIBB - QTRLY REVENUE UP 8 PERCENT TO $5.69 BILLION.BRISTOL-MYERS SQUIBB - QTRLY ELIQUIS WORLDWIDE REVENUE $1.58 BILLION, UP 28 PERCENT.BRISTOL-MYERS SQUIBB - QTRLY OPDIVO WORLDWIDE REVENUE $1.79 BILLION, UP 42 PERCENT.BRISTOL-MYERS SQUIBB - QTRLY YERVOY WORLDWIDE NET SALES $382 MILLION, UP 18 PERCENT.BRISTOL-MYERS SQUIBB - QTRLY SPRYCEL WORLDWIDE NET REVENUE $491 MILLION, DOWN 4 PERCENT.BRISTOL-MYERS SQUIBB - INCREASING 2018 GAAP EPS GUIDANCE RANGE TO $3.05 - $3.15.BRISTOL-MYERS SQUIBB SEES 2018 WORLDWIDE REVENUE INCREASING IN HIGH-SINGLE DIGITS; SEES 2018 GROSS MARGIN AS PERCENT OF REVENUE TO BE ABOUT 71 PERCENT.BRISTOL-MYERS SQUIBB - INCREASING 2018 NON-GAAP EPS GUIDANCE RANGE TO $3.80 - $3.90.Q3 EARNINGS PER SHARE VIEW $0.91, REVENUE VIEW $5.72 BILLION -- THOMSON REUTERS I/B/E/S.FY2018 EARNINGS PER SHARE VIEW $3.64, REVENUE VIEW $22.40 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Opdivo Plus Low-Dose Yervoy Shows Durable Clinical Benefit In Previously Untreated Patients With MSI-H
Monday, 22 Oct 2018 

Oct 22 (Reuters) - Bristol-Myers Squibb Co ::OPDIVO (NIVOLUMAB) PLUS LOW-DOSE YERVOY (IPILIMUMAB) DEMONSTRATES DURABLE CLINICAL BENEFIT IN PREVIOUSLY UNTREATED PATIENTS WITH MSI-H OR DMMR METASTATIC COLORECTAL CANCER.BRISTOL-MYERS SQUIBB CO - COMBINATION SHOWED 60% OBJECTIVE RESPONSE RATE (INVESTIGATOR-ASSESSED).BRISTOL-MYERS SQUIBB CO - 82% OF RESPONSES ONGOING AT TIME OF DATA CUTOFF; MEDIAN DURATION OF RESPONSE NOT YET REACHED.BRISTOL-MYERS SQUIBB CO - GRADE 3-4 TREATMENT-RELATED ADVERSE EVENTS (TRAES) OCCURRED IN SEVEN PATIENTS IN STUDY.BRISTOL-MYERS SQUIBB CO - GRADE TRAES LEADING TO TREATMENT DISCONTINUATION OCCURRED IN THREE PATIENTS IN TRIAL.  Full Article

Bristol-Myers Says BMS-986165 Delivered Significant Skin Clearance In Phase 2 Trial
Wednesday, 12 Sep 2018 

Sept 12 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB SAYS ANNOUNCED RESULTS FROM PHASE 2 STUDY OF BMS-986165, A TYK2 INHIBITOR, IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS.BRISTOL-MYERS SAYS BMS-986165 DELIVERED SIGNIFICANT SKIN CLEARANCE IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN PHASE 2 TRIAL.BRISTOL-MYERS SAYS EFFICACY ENDPOINTS IN PHASE 2 STUDY OF BMS-986165 WERE ACHIEVED AFTER 12 WEEKS OF TREATMENT WITH ≥3 MG DAILY OF BMS-986165.  Full Article

Replimune Announces FDA Acceptance Of Application For Lead Oncolytic Immunotherapy Rp1
Thursday, 6 Sep 2018 

Sept 6 (Reuters) - Replimune Group Inc ::REPLIMUNE ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR ITS LEAD ONCOLYTIC IMMUNOTHERAPY CANDIDATE, RP1.REPLIMUNE GROUP INC - INTENDS TO OPEN ITS ONGOING PHASE 1/2 CLINICAL TRIAL IN U.S. AND BEGIN ENROLLING PATIENTS IN Q4.REPLIMUNE - IN PART 1 OF PHASE 1/2 TRIAL, CO IS ASSESSING SAFETY AND TOLERABILITY OF RP1 ADMINISTERED ALONE IN PATIENTS WITH ADVANCED SOLID TUMORS.REPLIMUNE GROUP - PART TWO OF PHASE 1/2 CLINICAL TRIAL FOR RP1 EXPECTED TO INITIATE IN FIRST HALF OF 2019.REPLIMUNE - PART 2 OF PHASE 1/2 TRIAL IS EXPECTED TO BE INITIATED IN H1 2019.REPLIMUNE GROUP - IN PART TWO OF PHASE 1/2 CLINICAL TRIAL CO INTENDS TO STUDY SAFETY & EFFICACY OF RP1 IN COMBINATION WITH NIVOLUMAB.  Full Article

U.S. Food And Drug Administration Accepts Bristol-Myers Squibb’S Application For Sprycel
Thursday, 30 Aug 2018 

Aug 30 (Reuters) - Bristol-Myers Squibb Co ::U.S. FOOD AND DRUG ADMINISTRATION ACCEPTS BRISTOL-MYERS SQUIBB’S APPLICATION FOR SPRYCEL (DASATINIB) IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA.BRISTOL-MYERS SQUIBB CO - APPLICATION BASED ON RESULTS FROM PHASE 2 CA180-372 STUDY.BRISTOL-MYERS SQUIBB CO - FDA ACTION DATE IS DECEMBER 29, 2018.BRISTOL-MYERS SQUIBB CO - FDA ACTION DATE IS DECEMBER 29, 2018..  Full Article

Photo

Roche's lung cancer combo treatment wins FDA approval

Swiss drugmaker Roche Holding AG said on Thursday that its Tecentriq immunotherapy in combination with Avastin and chemotherapy won U.S. Food and Drug Administration approval as a first-line treatment for a type of lung cancer.